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Edited by Robert BaroukiAbstract We have identiﬁed a novel CARD-containing protein
from EST database, BinCARD (Bcl10-interacting protein with
CARD). BinCARD was ubiquitously expressed. Co-immunopre-
cipitation, In vitro binding, mammalian two-hybrid, and immu-
nostaining assays revealed that BinCARD interacted with
Bcl10 through CARD. BinCARD potently suppressed NF-jB
activation induced by Bcl10 and decreased the amounts of phos-
phorylated Bcl10. Mutations at the residue Leu17 or Leu65,
which is highly conserved in CARD, abolished the inhibitory ef-
fects of BinCARD on both Bcl10-induced activation of NF-jB
and phosphorylation of Bcl10. Further, expression of BinCARD
inhibited Bcl10 phosphorylation induced by T cell activation sig-
nal. These results suggest that BinCARD interacts with Bcl10 to
inhibit Bcl10-mediated activation of NF-jB and to suppress
Bcl10 phosphorylation.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Apoptosis plays a role not only in the development and
homeostasis of multicellular organism but also in the patho-
genesis [1]. Apoptotic signals are mediated by the association
of proteins containing homologous domains, such as death do-
main (DD), death eﬀector domain (DED), and caspase recruit-
ment domain (CARD) [2]. The CARD was ﬁrst identiﬁed in
caspases and their adaptor molecules. Recently, several
CARD-containing proteins have been identiﬁed (Bcl10,
CARD8/TUCAN, CARD10, CARD11, and CARD14), the
function of which appears to be directed primarily toward reg-
ulation of nuclear factor-jB (NF-jB) [3–6]. Mutations in the
CARD-containing molecules are associated with diseases;
mutation in Bcl10 is related with lymphoma of mucosa-associ-Abbreviations: CARD, caspase recruitment domain; BinCARD, Bcl10-
interacting protein with CARD; GST, glutathione S-transferase;
NF-jB, nuclear factor-jB; HA, hemagglutinin
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doi:10.1016/j.febslet.2004.10.094ated lymphoid tissue [7]. ASC, apoptosis-associated speck-like
protein-containing CARD, is also associated with familiar
Mediterranean fever [8].
Bcl10 (also known as CIPER/c-CARMEN/CLAP/c-E10)
has found to be essential for NF-jB activation in T or B cells
[3,9]. Bcl10 (/) lymphocytes fail to activate NF-jB in re-
sponse to CD3, CD3/CD28, and IgM ligation [10]. Several
CARD family proteins also have been described to drive
NF-jB activation through association with Bcl10 [5]. Thus,
Bcl10 is an important convergence for CARD-containing pro-
teins that regulate NF-jB activation. Here, we describe a novel
protein that contains an N-terminal CARD. It interacts with
Bcl10 through CARD and downregulates NF-jB activation
induced by Bcl10, named BinCARD (Bcl10-interacting protein
with CARD).2. Materials and methods
2.1. Database search
A BinCARD cDNA (GenBank Accession No. AK057716) was iden-
tiﬁed by searching the expressed sequence tag (EST) databases of Gen-
Bank using the nucleotide sequence encoding a CARD as a query
with the blastn program.2.2. Antibodies and reagents
Polyclonal anti-BinCARD antibody was generated against puriﬁed
glutathione S-transferase (GST)–CARD fusion proteins of BinCARD.
Anti-Bcl10 antibody (SC-331.3) was purchased from Santa Cruz Bio-
technology, Inc. PMA with ionomycin (Sigma) and anti-CD3 with
anti-CD28 antibodies (BD Biosciences) were used for stimulation of
Jurkat cells.2.3. Plasmid construction
The plasmids were generated with standard polymerase chain reac-
tion (PCR) using the following primer pairs: pBinCARD, 5 0-CCG
GAATTCATGACAG ATCAGACCTATTGTG-3 0, 5 0-GCTCTAG-
ACTAGGAGCGCCATGCAGC-30; pHA-BinCARD-N, 5 0-CCG-
GAATTCATGACAGATCAGACCTATTGTG-3 0, 5 0-CCTAGTCT-
AGAATCTGAGTTCTGCAGAGC-3 0; and pHA-BinCARD-C, 5 0-
GCGAATTCCGTAAGTTCCACATCACC-3 0, 5 0-GCTCTAGATA-
GGAGCGCCATGCAGC-30. Site-directed mutagenesis was per-
formed using the following primer pairs: pBinCARD-L17A, 5 0-CAG-
GACACGCCTTTCCCGACAGGCCATGGGCGC-3 0, 5 0-GCGCC-
CATGGCCTGTCGGGAAAGGCGTGTCCTG-3 0; pBinCARD-
L65A, 5 0-GTGCGGCTCTGTGACGCCCTGAGCCACCTGCAG-
30, 50-CTGCAGGTGGCTCAGGGCGTCACAGAGCCGCAC-30. pNF-
jB-luc and pbact-lacZ were previously described [11].ation of European Biochemical Societies.
Fig. 1. Sequence analysis of BinCARD. (A) Schematic representation
of the domain structure of BinCARD. (B) The predicted amino acid
sequence of BinCARD. The region encompassing the CARD motif is
underlined. (C) Alignment of the CARD of BinCARD with those of
the CARD-containing proteins. The conserved sequences are darkly
shaded. Predicted a-helixes (H) are indicated and asterisks represent
the residues mutated in the mutation analysis of BinCARD.
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Human MTN blot (Cat.#7780-1) was obtained from CLONTECH.
CARD of BinCARD cDNA was radiolabeled with [a-32P]dCTP,
hybridized, washed according to the manufacturers instructions, and
exposed to autoradiography ﬁlm.
2.5. Cell culture and transfection
HEK293T and HeLa cells were maintained in Dulbeccos modiﬁed
Eagles medium (DMEM, Life Technologies, Inc.) containing 10% fe-
tal bovine serum (Equi-bio Tech, Inc.). Jurkat cells were maintained in
RPMI1640 medium (Life Technologies, Inc.). Transfection was per-
formed as described earlier [11]. Jurkat cells were transfected with con-
trol or pbabe-BinCARD plasmid and selected with puromycin (1 lg/
ml) for stable single clone.
2.6. Luciferase and b-galactosidase assays
Luciferase activities of cell extracts were determined using a Lucifer-
ase Assay System (Promega). b-Galactosidase activity was examined
after mixing with b-galactosidase assay buﬀer (2·) containing 200
mM sodium phosphate (pH 7.3), 2 mM MgCl2, 100 mM b-mercap-
toethanol, and 1.33 mg/ml o-nitrophenyl-b-D-galactopyranoside. The
absorbance at 420 nm was measured using ELISA reader (Molecular
Device).
2.7. Mammalian two-hybrid assay
Cells were transfected with the following plasmids: pCMV-BD/Bin-
CARD, pCMV/AD fused to Bcl10 mutants, pFR-Luc ﬁreﬂy reporter
(Stratagene), and pbact-LacZ. The panel of CARD domains used
for the screen was described previously [6]. After 24 h, luciferase and
b-galactosidase activities were determined.
2.8. Immunoprecipitation
Cells were lyzed with RIPA buﬀer [50 mM Tris–HCl (pH 7.4), 1%
Nonidet P-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA,
1 mM PMSF, 1 lg/ml each of aprotinin, leupeptin, and pepstatin, 1
mM Na3VO4, and 1 mM NaF]. Immunoprecipitation was performed
with anti-hemagglutinin (HA) and protein-A-coupled Sepharose CL-
4B (Amersham–Pharmacia Biotech).
2.9. Immunostaining
Cells were ﬁxed with 4% paraformaldehyde for 15 min, permeabi-
lized with 0.1% Triton X-100 for 3 min, and incubated with primary
antibodies overnight at 4 C. Cells were incubated with FITC or
TRITC-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories Inc.) and bisbenzamide (Hoechst 33258). Fluorescent
images were observed under ﬂuorescence microscopy (LEICA).
2.10. Phosphatase assay
Cells were lyzed in phosphatase assay buﬀer [10 mM Tris–HCl (pH
7.4), 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1
lg/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na3VO4, and
1 mM NaF]. Cell lysates (20 lg) were incubated with calf intestine
phosphatase (New England Biolabs.) for 1 h at 37 C.Fig. 2. Expression of BinCARD mRNA and protein. (A) BinCARD
mRNA of human adult tissues was examined by Northern blot
analysis. (B) BinCARD protein of human adult tissues and cell lines
was examined by Western blot analysis using anti-BinCARD anti-
body.3. Results
3.1. Identiﬁcation and expression of BinCARD
To identify CARD-containing proteins, we screened public
database on the analysis of domain architectures (http://
SMART.embl-heidelberg.de). This search identiﬁed an EST
clone (GenBank Accession No. AK057716) encoding a 228-
amino acids protein with homology to a consensus CARD
(Fig. 1A). We termed this protein as BinCARD. Comparisons
of the cDNA sequence with the genomic sequences indicated
that BinCARD consists of four exons, spanning 17.14 kb on
chromosome 9q22.32. Alignment analyses revealed that the
N-terminal region of BinCARD (residues 8–100) shares signif-
icant sequence similarity with the CARD motifs of ced-3, cas-pase-1, caspase-2, caspase-4, caspase-5, and RAIDD (Fig. 1B
and C).
Northern blot analysis was performed to determine the dis-
tribution of BinCARD transcripts in human tissues using the
CARD of BinCARD as a probe. BinCARD transcript was de-
tected in all tissues examined: BinCARD was highly expressed
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2A). BinCARD protein was observed in a variety of human
tissues, Jurkat T cells, and DM4 melanoma cells examined
with Western blot analysis using anti-BinCARD antibody
(Fig. 2B).3.2. BinCARD binds to Bcl10 through CARD–CARD
interaction
The CARD mediates speciﬁc homophilic interaction with
other CARD-containing molecules. To identify the binding
partner of BinCARD, we performed a mammalian two-hybrid
screening of several CARD-containing proteins for their abil-
ities to interact with the CARD of BinCARD. CARD of Bin-
CARD speciﬁcally interacted with the CARD of Bcl10 and didFig. 3. Interaction of BinCARD with Bcl10 via CARD. (A) CARD of Bin
hybrid analysis. HEK293T cells were transfected with the reporter construc
containing proteins of pCMV-AD [9]. After 36 h, cells were collected and assa
protein interaction. (B) HEK293T cells were transfected with pCMV-BD/B
(Bcl10-N) deletion mutant of pCMV-AD/Bcl10 and then assayed for relative l
or GST-Bcl10 proteins bound to glutathione–Sepharose beads were incubated
co-transfected with pBinCARD and either pHA-Bcl10 (upper panel) or pH
anti-HA antibody and the immunoprecipitates and cell lysates were analyzed
transfected with pBincard and/or pHA-Bcl10. After 36 h, cells were stained by
ﬂuorescence was observed for Bcl10 (TRITC) and BinCARD (FITC). Nuclenot interact with CARD of BinCARD (Fig. 3A). To determine
the interaction motif of Bcl10, deletion mutants of Bcl10 were
generated. BinCARD interacted with Bcl10 through CARD
(Fig. 3B). A physical association between BinCARD and
Bcl10 was examined with in vitro assay (Fig. 3C). Pull-down
assay revealed that BinCARD directly associated with Bcl10
in vitro. However, introduction of the mutation in the highly
conserved leucine residue at 65 (L65A) of BinCARD abolished
its ability to bind to Bcl10 (Fig. 3C).
To examine an intracellular interaction of BinCARD with
Bcl10, HA-tagged Bcl10 and BinCARD expression plasmids
were transfected into HEK293T cells. Cell lysates were immu-
noprecipitated with the anti-HA antibody (Fig. 3D, upper
panel). Western blot analysis of the immunoprecipitates
showed that BinCARD and Bcl10 associated with each other.CARD interacts with CARD of Bcl10 examined by mammalian two-
t in combination with pCMV-BD/BinCARD and CARD of CARD-
yed for relative luciferase activity as a measure of intracellular protein–
inCARD and either wild type, N-terminal (Bcl10-C), or C-terminal
uciferase activity. (C) In vitro interaction of BinCARD and Bcl10. GST
with 35S-labeled BinCARD or L65A mutant. (D) HEK293T cells were
A-caspase-9 (lower panel). Immunuprecipitation was performed with
by Western blotting with anti-BinCARD antibody. (E) HeLa cells were
anti-Bincard and anti-HA antibodies. In lower panel, diﬀerent color of
i were stained by Hoechst 33258.
Fig. 4. Inhibition of Bcl10-induced activation of NF-jB by Bin-
CARD. (A) HEK293T cells were transfected with pNF-jB-luc and
either pcDNA3 or pBcl10, along with either wild type or deletion
mutants of BinCARD. pbact-lacZ was included as an internal control.
After 48 h, cell lysates were prepared and luciferase activities were
measured and normalized by b-galactosidase activity. Bars depict
means ± S.D. h indicates the statistical diﬀerence with respect to Bcl10
alone (p < 0.01). (B) Point mutants of L17A and L65A and DN
mutant of NIK (NIK-DN) were expressed with Bcl10 and NF-jB
reporter gene, and relative luciferase activities were determined. The
asterisk indicates the statistical signiﬁcance with respect to Bcl10 alone
(P < 0.03).
Fig. 5. Modulation of Bcl10 phosphorylation by BinCARD. (A) Cell
extracts were prepared from HEK293T cells expressing HA-Bcl10,
incubated with (+) or without () calf intestine phosphatase for 1 h at
37 C. (B) HEK293T cells were co-transfected with pHA-Bcl10 and
either pcDNA3 (Con), pBinCARD (WT), pBinCARD-N (N), pBin-
CARD-L17A (L17A), or pBinCARD-L65A (L65A). Cell extracts were
analyzed using anti-HA (upper panel), anti-BinCARD (middle panel),
or anti-Tubulin antibody (lower panel).
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did not interact with BinCARD (Fig. 3D, lower panel).
Further, co-expression of Bcl10 and BinCARD induced
translocation of BinCARD from nucleus to cytosol, while Bin-
card and Bcl10 were detected predominantly in nucleus and
cytoplasmic ﬁlaments, respectively (Fig. 3E). Similar change
in the subcellular localization of BinCARD-N (CARD of Bin-
card) was observed in the cells overexpressing Bcl10 (data not
shown). These results support that BinCARD interacts with
Bcl10 in cells.
3.3. BinCARD inhibits Bcl10-mediated activation of NF-jB
It has been found that CARD proteins can function as com-
ponents of signaling pathways that lead to activation of the
NF-jB [12]. We tested whether BinCARD could modulate
Bcl10-mediated activation of NF-jB using luciferase reporter
assay. As shown in Fig. 4A, expression of Bcl10 increased
NF-jB activity 10-fold compared with control. Interestingly,
expression of BinCARD or BinCARD-N exhibited inhibitory
eﬀects on Bcl10-induced activation of NF-jB. It has been re-
ported that point mutation and deletion of amino acids in
the CARD domain signiﬁcantly inﬂuenced the binding activity
and function of CARD proteins [3]. To characterize the
CARD of BinCARD in the inhibition of NF-jB activity, we
generated two point mutants of BinCARD replacing con-
served leucine residue with alanine (L17A and L65A) (Fig.
1C). Point mutations at 17 or 65 abolished the NF-jB inhibi-
tory activity of BinCARD (Fig. 4B). The dominant repressor
mutant of NIK (NIK-DN) eﬃciently blocked NF-jB activa-tion induced by Bcl10 [9]. Similar expression levels of the mu-
tants of BinCARD were conﬁrmed by immunoblotting (data
not shown).3.4. BinCARD reduces the phosphorylation of Bcl10
Bcl10 migrates on SDS–polyacrylamide gels as multiple
bands in size due to phosphorylation [9]. We observed that
slow migrating bands appeared to be phosphorylated forms
of Bcl10, since treatment of the cell lysates with phosphatase
eliminated the slowest migrating form (Fig. 5A). To examine
whether BinCARD can aﬀect on the phosphorylation of
Bcl10, Bcl10 was co-transfected with BinCARD. When ex-
pressed alone, the phosphorylated forms of Bcl10 were in-
creased by the treatment with phosphatase inhibitor, okadaic
acid (data not shown). Interestingly, co-expression of Bin-
CARD or BinCARD-N decreased the phosphorylated form
of Bcl10, the slow migrating band (Fig. 5B). Disappearance
of phosphorylated Bcl10 by BinCARD correlated with the
NF-jB inhibitory activity of BinCARD. L17A and L65A mu-
tants lacking NF-jB inhibitory activity could not reduce the
amounts of the phosphorylated Bcl10 (Fig. 5B, upper panel).
Western blot analysis revealed that the expression level of Bin-
CARD mutants was similar to wild type (Fig. 5B, middle pa-
nel). These data suggest that BinCARD inhibits the
phosphorylation of Bcl10 in a CARD-dependent manner.
3.5. BinCARD inhibits Bcl10 phosphorylation induced by T cell
activation signal
Bcl10 knockout (/) lymphocytes failed to activate NF-jB
in response to CD3, CD3/CD28, and IgM ligation [10] and
Bcl10 was phosphorylated and translocated to the lipid-raft
after T cell receptor activation [13]. To examine whether Bin-
CARD can function in T cell signaling, we generated stable
lines overexpressing BinCARD in Jurkat T cells. RT-PCR
was performed as described earlier [11] (Fig. 6A). Consistent
with the previous reports [16], co-stimulation of Jurkat-puro
control cells with anti-CD3/CD28 antibodies or with a combi-
Fig. 6. Suppression of Bcl10 phosphorylation by BinCARD during T cell activation signaling. (A) RT-PCR was performed using cDNAs prepared
from Jurkat-puro and Jurkat-BinCARD#44 cells. Actin was shown as control. (B) Cells were stimulated with PMA (20 ng/ml) and ionomycin
(IONO., 1 lM) for the indicated times. Cell extracts were analyzed with immunoblotting using anti-Bcl10, anti-BinCARD, anti-IjBa, and anti-
Tubulin antibodies. (C, D) Jurkat-puro and Jurkat-BinCARD#44 cells were stimulated with anti-CD3 (1 lg/ml) and anti-CD28 (1 lg/ml) antibodies
or TNF-a (20 ng/ml) for the indicated times. Bcl10 phosphorylation and IjBa degradation were examined by Western blot analysis.
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cin, which mimics the downstream events of TCR activation,
induced Bcl10 phosphorylation (Fig. 6B and C). However,
expression of BinCARD (BinCARD#44) suppressed Bcl10
phosphorylation and IjBa degradation induced by T cell acti-
vation signal (Fig. 6B and C). TNF-a-mediated degradation of
IjBa was normal in BinCARD#44 cells (Fig. 6D). These re-
sults suggest that BinCARD inhibits Bcl10 phosphorylation
by being recruited into the Bcl10 complexes during TCR acti-
vation signaling.4. Discussion
Knockout and transgenic studies reveal that the Bcl10-med-
iated activation pathway of NF-jB plays an essential role in
antigen receptor signaling in B and T cells [10]. Our ﬁnding
is that BinCARD binds to Bcl10 and inhibits NF-jB activa-
tion through its CARD. The inhibitory eﬀects of BinCARD
on NF-jB activity correlate with its binding ability to Bcl10.
CARD proteins that assemble with Bcl10, such as CARD9,
CARD10, CARD11, and CARD14, transduce upstream stim-
uli to the activation of NF-jB [5,6]. BinCARD may engage in
this signaling complex through interaction with Bcl10, which
deserves to be further elucidated.
Bcl10 is modiﬁed by phosphorylation [9,14,15] and the phos-
phorylation of Bcl10 might play a distinct role in the regula-
tion of NF-jB activation induced by T cell activation signal.
Our observations that the expression of BinCARD decreased
the phosphorylated form of Bcl10 suggest that BinCARD
might prevent the phosphorylation of Bcl10 by binding to it.
Co-immunoprecipitation and in vitro binding assays imply
that BinCARD may interact better with the unphosphorylated
form of Bcl10, leading us to propose that BinCARD may se-
cure Bcl10 inactive.
As a negative regulator of NF-jB activity, BinCARD might
also be recruited into the Bcl10 complexes to downregulate theNF-jB signaling during T cell activation. Recent report has
demonstrated that Carma1 is a component of Bcl10-mediated
NF-jB activation complexes [16]. However, our in vitro bind-
ing assays indicate that though Carma1 and BinCARD inter-
act with Bcl10, they do not compete with each other to bind to
Bcl10 (data not shown). In addition, phosphorylation of Bcl10
causes changes in its binding partners [14]. Thus, interference
of Bcl10 phosphorylation by BinCARD may alter the compo-
nents of the Bcl10-signaling complex, blocking the activation
of NF-jB. The presence of unidentiﬁed components in NF-
jB signaling triggered by antigen receptor is estimated to ﬁll
the remaining gaps in this pathway [17]. Further study aims
at molecular architecture of Bcl10-mediated NF-jB-signaling
complex and oﬀers an attractive perspective for the under-
standing of the growth regulation and pathological dysregula-
tion of the NF-jB pathway.
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